Efficacy and Safety Study of Icotinib in the Treatment of Patients with Advanced Non-Small Cell Lung

• 作 者: XiangleiMa[1]MeiqiShi[2]YingyingKou[2]LiWang[2]GuohaoXia[2]ShaorongYu[2]YingFang[2]YiqunTang[1]
• 机 构: Clinical Pharmacy Teaching and Research Section,China Pharmaceutical University,Nanjing 210009,China
• 出 处: 2014华东胸部肿瘤论坛暨第七届浙江省胸部肿瘤论坛
• 发表日期: 2014年期

　　Object To assess the efficacy and toxicity of icotinib,and to analyze possible factors influencing effectiveness in patients with advanced non-small cell lung cancer (NSCLC).Method The clinical data of 260 patients with NSCLC assigned to the Jiangsu Cancer Hospital were retrospectively analyzed.Result 256 patients were evaluable for efficacy except 4 patients did not tolerate the side effects to stop taking the medicine.Among the 256 patients,there was no complete response (CR),96 (37.5%) patients with partial response (PR),97 (37.9%) patients with stable disease (SD) and 63(24.6%) patients with progression disease (PD).The overall progression-free survival (PFS) was 7 months.The PFS after first-line treatment, second-line treatment, and third or more than third line treatment were 11 (1 ~ 16.3), 6(0.4~11.3), 5(1 ~ 13.5) months, respectively.Conclusion Icotinib is effective and well safety in patients with advanced non-small cell lung cancer.